MX2009004792A - Moduladores de la union de pai-1 para el tratamiento de trastornos oculares. - Google Patents
Moduladores de la union de pai-1 para el tratamiento de trastornos oculares.Info
- Publication number
- MX2009004792A MX2009004792A MX2009004792A MX2009004792A MX2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A
- Authority
- MX
- Mexico
- Prior art keywords
- pai
- treatment
- binding
- glaucoma
- compound
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 abstract 4
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 abstract 4
- 208000010412 Glaucoma Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 102100035140 Vitronectin Human genes 0.000 abstract 1
- 108010031318 Vitronectin Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000001585 trabecular meshwork Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En una modalidad, la invención se refiere a un método de tratamiento del glaucoma o la PtO elevada en un paciente, que comprende administrar al paciente una cantidad efectiva de una composición que comprende un agente que modula la unión de PAI-1 a vitronectina; en otra modalidad, la invención se refiere a un método de fabricación de un compuesto para ser usado en el tratamiento del glaucoma o la PIO elevada, que comprende proveer una sustancia candidata que se sospecha que modula la unión de PAI-1, seleccionar el compuesto evaluando la capacidad de la sustancia candidata para disminuir la cantidad de PAI-1 activo en la red trabecular de un sujeto que padece glaucoma o PIO elevada, y fabricar el compuesto seleccionado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86371506P | 2006-10-31 | 2006-10-31 | |
| PCT/US2007/083170 WO2008055205A2 (en) | 2006-10-31 | 2007-10-31 | Pai-1 binding modulators for the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004792A true MX2009004792A (es) | 2009-05-21 |
Family
ID=39345074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004792A MX2009004792A (es) | 2006-10-31 | 2007-10-31 | Moduladores de la union de pai-1 para el tratamiento de trastornos oculares. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20080107644A1 (es) |
| EP (1) | EP2077829A2 (es) |
| JP (1) | JP2010508306A (es) |
| KR (1) | KR20090082401A (es) |
| CN (1) | CN101588798A (es) |
| AU (1) | AU2007313684A1 (es) |
| CA (1) | CA2666316A1 (es) |
| MX (1) | MX2009004792A (es) |
| RU (1) | RU2465898C2 (es) |
| WO (1) | WO2008055205A2 (es) |
| ZA (1) | ZA200902453B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090202524A1 (en) * | 2007-10-31 | 2009-08-13 | Alcon Research, Ltd. | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
| US20100158897A1 (en) * | 2006-10-31 | 2010-06-24 | Alcon Research, Ltd. | Pai-1 modulators for the treatment of ocular disorders |
| US9448234B2 (en) | 2011-11-15 | 2016-09-20 | National University Corporation Hamamatsu University School Of Medicine | Therapeutic agent for preterm delivery or abortion using plasminogen activator inhibitor-1 |
| US10946076B2 (en) | 2013-02-13 | 2021-03-16 | The Research Foundation For The State University Of New York | Glaucoma treatment |
| US9820954B2 (en) * | 2015-08-19 | 2017-11-21 | Jenivision Inc. | Quantitative peri-orbital application of ophthalmology drugs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2102069C1 (ru) * | 1992-05-22 | 1998-01-20 | Сендзю Фармасьютикал Ко., Лтд. | Фармацевтическая композиция для лечения глаукомы |
| AR002194A1 (es) * | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
| AU770365B2 (en) * | 1998-12-11 | 2004-02-19 | Bakulesh Mafatlal Khamar | The process for manufacturing formulation of topical beta blockers with improved efficacy |
| AU771635B2 (en) * | 1999-01-05 | 2004-04-01 | American National Red Cross, The | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| CA2476761A1 (en) * | 2002-02-19 | 2003-08-28 | Vanderbilt University | Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| US7351407B2 (en) * | 2002-04-30 | 2008-04-01 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
-
2007
- 2007-10-31 ZA ZA200902453A patent/ZA200902453B/xx unknown
- 2007-10-31 KR KR1020097010021A patent/KR20090082401A/ko not_active Withdrawn
- 2007-10-31 MX MX2009004792A patent/MX2009004792A/es not_active Application Discontinuation
- 2007-10-31 AU AU2007313684A patent/AU2007313684A1/en not_active Abandoned
- 2007-10-31 RU RU2009120545/15A patent/RU2465898C2/ru not_active IP Right Cessation
- 2007-10-31 CN CNA2007800407976A patent/CN101588798A/zh active Pending
- 2007-10-31 WO PCT/US2007/083170 patent/WO2008055205A2/en not_active Ceased
- 2007-10-31 EP EP07868631A patent/EP2077829A2/en not_active Withdrawn
- 2007-10-31 US US11/931,393 patent/US20080107644A1/en not_active Abandoned
- 2007-10-31 JP JP2009534946A patent/JP2010508306A/ja active Pending
- 2007-10-31 CA CA002666316A patent/CA2666316A1/en not_active Abandoned
-
2010
- 2010-06-25 US US12/823,773 patent/US20100260784A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200902453B (en) | 2010-07-28 |
| WO2008055205A3 (en) | 2008-07-17 |
| KR20090082401A (ko) | 2009-07-30 |
| US20080107644A1 (en) | 2008-05-08 |
| WO2008055205A2 (en) | 2008-05-08 |
| RU2009120545A (ru) | 2010-12-10 |
| AU2007313684A1 (en) | 2008-05-08 |
| US20100260784A1 (en) | 2010-10-14 |
| CN101588798A (zh) | 2009-11-25 |
| EP2077829A2 (en) | 2009-07-15 |
| JP2010508306A (ja) | 2010-03-18 |
| CA2666316A1 (en) | 2008-05-08 |
| RU2465898C2 (ru) | 2012-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX351152B (es) | Compstatina y analogos de la misma para tratar trastornos oculares. | |
| CY1112238T1 (el) | Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων | |
| WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
| DE602006009834D1 (de) | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung | |
| WO2001087328A3 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
| MA29785B1 (fr) | Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr | |
| TW200714283A (en) | Method and composition for treating peripheral vascular diseases | |
| EA200900663A1 (ru) | Лечение синдрома "сухого глаза" | |
| MX2009010854A (es) | Composiciones y metodos para profilaxis y tratamiento de adicciones. | |
| TW200833842A (en) | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents | |
| PA8778101A1 (es) | Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13 | |
| MX2007010560A (es) | Roflumilast para el tratamiento de diabetes mellitus. | |
| BRPI0414277A (pt) | métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2 | |
| WO2006015775A3 (en) | Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | |
| MA30604B1 (fr) | Agonistes de ep2 | |
| NO20082894L (no) | Metode for behandling av kognitiv dysfunksjon | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| EP2340258A4 (en) | PROCESS FOR THE SYNTHESIS AND APPLICATIONS OF INHIBITORS OF GHRELIN-O-ACYLTRANSFERASE AS POTENTIAL THERAPEUTIC AGENTS AGAINST OBESITAS AND DIABETES | |
| SG171602A1 (en) | Use of antisecretory factors for treating intraocular hypertension | |
| BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
| WO2008055205A3 (en) | Pai-1 binding modulators for the treatment of ocular disorders | |
| ATE384529T1 (de) | Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen | |
| WO2006020680A3 (en) | Heterocyclic compounds as pharmaceutical agents | |
| WO2009131850A3 (en) | Pai-1 expression and activity inhibitors for the treatment of ocular disorders | |
| MX2007010295A (es) | Composiciones oftalmologicas novedosas y metodo para su uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |